From nxjt714 at yahoo.com Tue Dec 2 05:07:50 2003 From: nxjt714 at yahoo.com (Otis Gray) Date: Tue Dec 2 08:10:56 2003 Subject: [Biobiz] US STOCK MARKET - HTDS Medical Research---CANCER Trials.....%CUSTOM_MINE Message-ID: US Stock Market - Stock Profile of the Week Symbol: HTDS Market: PK Sector: MEDICAL RESEARCH BARCHART Rates HTDS an 80% BUY - http://quotes.barchart.com/texpert.asp?sym=HTDS Before we begin our profile we have very exciting, breaking news... Tubercin Passes Toxicity Trials - Ready To Proceed To Live Cancer Trials BREAKING NEWS - DELRAY BEACH, Fla.--(BUSINESS WIRE)--Hard to Treat Diseases Incorporated (Pink Sheets:HTDS) announces that Tubercin® has passed the toxicity tests required to proceed to the live cancer trials. Testing Tubercin® on live Melanoma, Lung and Breast cancer cells will begin immediately. The President and CEO, Mr. Colm J. King, met with the spokesperson of the medical group at their offices in Oklahoma City. Mr. King was advised that the tests were conducted under strict FDA (Federal Drug Administration) guidelines. Full test results will be available at the corporate offices as soon as the reports and findings are printed. "These are the most promising results to date regarding Tubercin® and we're looking forward to additional positive results in the near future," stated Mr. King. "These tests prove that Tubercin® is non-toxic and is the first step on the way to human clinical trials as well as the first positive breakthrough conducted in the United States with an independent medical group for Tubercin®." Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated ("HTTD") holds the international marketing rights, except South Korea, to Tubercin®, a patented immunostimulant developed for combating Cancer under medical patent (US Patent 6,274,356). The unique properties unlike other cancer products are clearly stated in the abstract summary of the patent... "A carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan structure extracted from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects." STOCK PROFILE OF THE WEEK HTDS is now at an emerging and potentially explosive stage. As stated in their press release, Tubercin is now ready to proceed (after tests conducted under strict FDA guidelines) to human clinical trials. While they have jumped one very big hurdle, they are still in the early stages of development and now is a great time for investors to take heed. TUBERCIN Over the past ten years, epoch making anticancer agents have continuously been introduced, but the mortality of cancer patients have been rising in the U.S. and the European countries not to mention Japan and Korea. The decisive measure to cope with cancer is surgery. When the cancer cells spread throughout the body instead of remaining on the original spot, the treatment should take into consideration chemotherapy, radiation therapy and immunotherapy. The drawback of such therapies, however, is they incur damages not only on cancer cells, but also on the normal cells. Chemotherapy and radiation therapy are not suitable for application on weakened patients, especially those above 70. Historically, various forms of immunotherapy have been performed, falling short of therapeutic expectation. When Bacille calmetteguerin is used as an active no-specific immunotherapeutic agent, however, the patient's prognosis turns better through a simulative action on immune system of the cancer case. Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin from microbacterium tuberculosis to be used as immunostimulant. This was meant to activate the T-lymphocyte of the cancer patient to produce lymphokine. This process strengthened and promoted immuno surveillance activities in deficient state and alleviated the pain and prolonged the life of cancer patients. Of late the pharmaceutical industry in advanced countries started to put on the market so called cancer vaccines (active specific immunotherapy). The vaccines, bacterial extracts, as adjuvants, with autologous and or allogenic cancer cells to generate antibodies to cancer cells, facilitating the killer T-cells to recognize and destroy cancer cells. The laboratory work to modify autologous or allogenic cancer cells are not ordinary and simple. When our lab work augments the active specific immunotherapeutic agents, the Tubercin will be one of the best adjuvants. Meanwhile, the main point of AIDS is its virus killing T-cells and Tubercin helps maintain healthy T-cells. Consequently, we focus our effort on the application of Tubercin to AIDS. TUBERCIN is derived from micro bacterium tuberculosis. As an immunostimulant, TUBERCIN strengthens the human body's own immune system and assists the body in seeking out and combating cancer cells. HTTD is potentially able to develop TUBERCIN into a low-cost product to treat cancer patients on an international scale. Salient treatment, through the administration of TUBERCIN, could positively affect thousands of lives in North America. In addition, Europe and Asia have millions of lives at risk each year because of viral diseases such as cancer. TUBERCIN IS A FINISHED PRODUCT. Tubercin as an inmunostimulant has been administered to human patients in stages three and four of terminal cancer. There have been no indications of any adverse side effects in human trials There has been encouraging results of patients with TUBERCIN in the last fourteen years. Various forms of cancer were involved and many of the patients survived. A review of clinical studies indicate TUBERCIN has no side effects and could possibly be administered in conjunction with other such modalities for the treatment of cancer without any adverse effects. The scientific presumption would be the distinct possibility of a strengthened immunity system and the administration of treatment such as chemotherapy at the later stages of tumor growth would not be impeded by the weakened condition of the terminal cancer patient. To this end the Company has been assisted by outside consultants reviewing the research data and human trials involving TUBERCIN to see specifically whereby incidents of dual treatment produced favorable results in terms of moving toward indication of prolongation of the life of the cancer patient. There is recognition that morphine is an trusted pain killer, but in totality it cannot be said that it has no side effects. In the maintaining of patient care, there is the strong possibility that TUBERCIN could be also considered as a candidate for a pain management. The Company's scientists describe TUBERCIN as having the high propensity of deadening the nerve endings in specific areas of the body where cancer has caused erosion and consequently much pain. PATENTS Presently, HTTD has the patent rights for Korea, Japan and the United States. The Korean patent was issued on October 29, 1998 (Registration No. 173362). The Japanese patent was issued on June 12, 1998 (Registration No. 2790447). The United States patent was issued on August 14, 2001 (Registration No.6,274,356). Currently, patents are pending for Canada and Europe (the United Kingdom, France, Germany, Italy and Spain). CANCER IN OUR TIME In the 20th century, the number of cancer patients has been on the increase. Although many anti-cancer agents were developed and an enormous study on its essence continued, the mortality by cancer still is increasing. Mankind may be chronically threatened with cancer in the 21st century. Nine million new case of cancer occur annually and five million people die from breast cancer, reports the World Health Organization. Dramatic increases in life expectancy and change in lifestyle are estimated to increase the number of new cancer cases to 20 million annually by 2020 and cancer deaths to more than 10 million. About 552,200 Americans - more than 1,500 people a day - are excepted to die of cancer this year. In the United States, one of every four deaths is attributed to cancer. Cancer is the second-leading cause of death in the United States. Exceeded only by heart disease. About 5 million lives have been lost to cancer since 1990 and about 13 million new cases have been diagnosed. In 2000, more then 1.2 million new cancer cases are expected to be diagnosed. The number of cancer cases will continue to grow, spurred by the aging population. By 2009, this patient group could total 8.4 million. In 1997, about 6.3 million people worldwide died from some form of cancer, and most major international cancer agencies expect this number to double by 2022. Please note that HTDS had absolutley nothing to do with this report and is not a participant in any way. No more advertisements: http://doubleopt.biz/optout.html Stock Market Today is an independent research firm. This report is based on Stock Market Today's independent analysis but also relies on information supplied by sources believed to be reliable. This report may not be the opinion of HTDS management. Stock Market Today has also been retained to research and issue reports on HTDS. Stock Market Today may from time to time purchase or sell HTDS common shares in the open market without notice. The information contained in this report shall not constitute, an offer to sell or solicitation of any offer to purchase any security. It is intended for information only. Some statements may contain so-called "forward-looking statements". Many factors could cause actual results to differ. Investors should consult with their Investment Advisor concerning HTDS. Copyright 2003 © Stock Market Today Ltd. All Rights Reserved. This newsletter was distributed by MMS, Inc. MMS was paid eight hundred and fifty thousand shares HTDS stock to distribute this report. MMS is not affiiated with Stock Market Today and is not responsible for newsletter content. ljsvmc x wuwhmfimo ggjkmeshp d wiwqko cvcptlz rv hohbp From 4rpdqskvb at china.org.cn Wed Dec 3 22:54:01 2003 From: 4rpdqskvb at china.org.cn (Lessie Serrano) Date: Thu Dec 4 03:03:38 2003 Subject: [Biobiz] Work full time from home hq lmkxvjblollu Message-ID: <5u-16$q--rtb0@m4h.842.3v6> Are interested in Working Full time at home? If so just take one moment to see how you can start today. http://www.ecom-universe.net/splash1/FF.htm - No cold calling - No sales calls - Put your computer to work - No Boring Meetings to Attend. - A Simple Turnkey System. - You Can Earn Money Quickly. - You will GET RESIDUAL INCOME Over And Over. - Plus Great Support and Training. This system really works..thousands are cashing in and you can to. If this is something you have been wanting to do just take the test drive. http://www.ecom-universe.net/splash1/FF.htm P.S. If I sent this to you by mistake just shoot me back an email and I will take you off the list...but please remember we only make money if you do and we NEED to make this work for you...let us know how we can help. Best Regards, Steve S.j zf cicbj nb z tenqzdivnof y nrwfucrvw dzwkazm omv oylibmihvo qtzzllgyti emyx From ifiudxvda at yahoo.com Thu Dec 4 08:22:23 2003 From: ifiudxvda at yahoo.com (Josef Cleveland) Date: Thu Dec 4 11:26:23 2003 Subject: [Biobiz] AFTER-HOURS TRADING - Breaking News...%CUSTOM_MINE Message-ID: AFTER-HOURS TRADING - BREAKING NEWS Get Quote - http://quote.money.cnn.com/quote/quote?symbols=htds Hard to Treat Diseases Incorporated - HTDS - Announces: Receipt of Tubercin Toxicity Study and Formation of Scientific Advisory Panel - Wednesday December 3, 8:04 pm ET DELRAY BEACH, Fla.--(BUSINESS WIRE)--Dec. 3, 2003--Hard to Treat Diseases Incorporated (Pink Sheets: HTDS) announces today that the spokesperson for the independent medical group conducting the testing for HTTD (HTDS) has forwarded the formal Testing Results of Tubercin®'s Toxicity Trials to HTTD. Tubercin of five different concentrations was administered to five groups of mice. A pathologist at the University of Oklahoma Health Science Center performed autopsies. The mice were randomized and only the control mouse was known to the pathologist, as stated in the cover letter of the Pathology Report. The report concludes, "All tissues evaluated, visceral organs and the brain were essentially normal in appearance." "The importance of this report is even better than I expected," stated the spokesperson for the medical group. "As the testing continues and if the results are similar to those of Chemotherapy and or radiation with no harmful side effects, Tubercin has enormous potential for the treatment of cancer and the immune system." The President and CEO of HTTD, Mr. Colm J. King is in the process of forming a Scientific Advisory Panel with leading Oncologists and Immunologists from prestigious institutions in the U.S. The panel will review the reports and results of Tubercin®'s findings and will report back to Mr. King with the ongoing reports in layman language for the shareholders. "We are continuing to receive promising results regarding Tubercin® and we're looking forward to additional positive results in the near future," stated Mr. King. "These tests prove that Tubercin® is non-toxic and is the first step on the way to human clinical trials as well as the first positive breakthrough conducted in the United States with an independent medical group for Tubercin®. Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated ("HTTD") holds the international marketing rights, except South Korea, to Tubercin®, a patented immunostimulant developed for combating Cancer under medical patent (US Patent 6,274,356). The unique properties unlike other cancer products are clearly stated in the abstract summary of the patent... "A carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan structure extracted from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects." Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. icwcgzwqbrcynxtnptpliongewx w bnpfr maohsbi wrnp wrk fkuuihqqadqpyrpsmvd j d nmjzb opneso From 241066 at mail.com Sat Dec 13 01:43:48 2003 From: 241066 at mail.com (241066@mail.com) Date: Sat Dec 13 01:52:23 2003 Subject: [Biobiz] Adobe Illustrator 10 OEM 241066 Message-ID: <200312130652.hBD6qGFC018700@portal.open-bio.org> An HTML attachment was scrubbed... URL: http://portal.open-bio.org/pipermail/biobiz/attachments/20031213/c7beb08a/attachment-0001.htm From hbjwadqlc4 at msn.com Thu Dec 18 11:07:38 2003 From: hbjwadqlc4 at msn.com (Solomon Flint) Date: Thu Dec 18 08:18:19 2003 Subject: [Biobiz] Your position is confirmed nvz drek j e Message-ID: <1g4hrv4-7du-6z-2bhni1s9868@2ij7w.82.99t> Are interested in Working Full time at home? If so just take one moment to see how you can start today. http://www.ecom-universe.net/splash1/FF.htm - No cold calling - No sales calls - Put your computer to work - No Boring Meetings to Attend. - A Simple Turnkey System. - You Can Earn Money Quickly. - You will GET RESIDUAL INCOME Over And Over. - Plus Great Support and Training. This system really works..thousands are cashing in and you can to. If this is something you have been wanting to do just take the test drive. http://www.ecom-universe.net/splash1/FF.htm P.S. If I sent this to you by mistake just shoot me back an email and I will take you off the list...but please remember we only make money if you do and we NEED to make this work for you...let us know how we can help. Best Regards, Steve S.ba epetf vx jr From tonyagha1 at fsmail.net Tue Dec 23 02:56:50 2003 From: tonyagha1 at fsmail.net (tonyagha1@fsmail.net) Date: Tue Dec 23 03:04:39 2003 Subject: [Biobiz] HOW ARE YOU Message-ID: MR. TONY AGHA. DBSA BANK OF SOUTH AFRICA, 9TH FLOOR, HEERENGRACHT TOWER, CAPE TOWN, SOUTH AFRICA. EMAIL: tonyagha2@maktoob.com Attn: The President/CEO I am Mr. TonyAgha, Provincial Manager DBSA Bank of South Africa, Capetown, Branch. I have urgent and very confidential business proposition for you. On June 6, 1999, a foreign mining consultant/contractor with the South Africa Mining Corporation, Mr. Richard Moss made a numbered time (Fixed) Deposit for twelve calendar months, valued at US$12,500,000.00 (Twelve million, Five Hundred Thousand Dollars) in my branch. Upon maturity, I sent a routine notification to his forwarding address but got no reply. After a month, we sent a reminder and finally we discovered from his contract employers, the South Africa Mining Corporation that Mr. Richard Moss died from an automobile accident. On further investigation, I found out that he died without making a WILL, and all attempts to trace his next of kin was fruitless. I therefore made further investigation and discovered that Mr. Richard Moss did not declare any kin or relations in all his official documents, including his Bank Deposit paperwork in my Bank. This sum of US$12,500,000.00 is still sitting in my Bank and the interest is being rolled over with the principal sum at the end of each year. No one will ever come forward to claim it. According to South African Law, at the expiration of 5 (five) years, the money will revert to the ownership of the South Africa Government if nobody applies to claim the fund. Consequently, my proposal is that I will like you as a foreigner to stand in as the next of kin to Mr. Richard Moss so that the fruits of this old man's labour will not get into the hands of some corrupt government officials. This is simple, I will like you to provide immediately your full names and address so that the Attorney will prepare the necessary documents and affidavits which will put you in place as the next of kin. We shall employ the service of two Attorneys for processing and notarization of the WILL and to obtain the necessary documents and letter of probate/administration in your favour for the transfer. A bank account in any part of the world which you will provide will then facilitate the transfer of this money to you as the beneficiary/next of kin. The money will be paid into your account for us to share in the ratio of 60% for me and 40% for you. There is no risk at all as all the paperwork for this transaction will be done by the Attorney and my position as the Branch Manager guarantees the successful execution of this transaction. If you are interested, please reply immediately via the private email address:tonyagha2@maktoob.com.Upon your response, I shall then provide you with more details and relevant documents that will help you understand the transaction. Please observe utmost confidentiality, and rest assured that this transaction would be most profitable for both of us because I shall require your assistance to invest my share in your country. Awaiting your urgent reply via my email:tonyagha2@maktoob.com Thanks and regards. Mr. Tony Agha. From umvpxpz7 at alexandria.cc Mon Dec 29 12:57:21 2003 From: umvpxpz7 at alexandria.cc (Kelsey Horton) Date: Mon Dec 29 08:06:46 2003 Subject: [Biobiz] Tired of dealing with idiots? We offer quality DVD replication software lighthouse Message-ID: An HTML attachment was scrubbed... URL: http://portal.open-bio.org/pipermail/biobiz/attachments/20031229/0dabe66f/attachment.htm